Marshall Wace North America L.P. reduced its stake in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 28.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 211,069 shares of the biopharmaceutical company’s stock after selling 84,689 shares during the period. Marshall Wace North America L.P. owned 0.36% of Agios Pharmaceuticals worth $16,278,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors also recently modified their holdings of AGIO. First Trust Advisors LP lifted its stake in shares of Agios Pharmaceuticals by 58.8% in the 3rd quarter. First Trust Advisors LP now owns 1,162,010 shares of the biopharmaceutical company’s stock worth $89,614,000 after acquiring an additional 430,216 shares during the period. Woodford Investment Management Ltd acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $32,849,000. Wells Fargo & Company MN lifted its stake in shares of Agios Pharmaceuticals by 459.8% in the 2nd quarter. Wells Fargo & Company MN now owns 407,393 shares of the biopharmaceutical company’s stock worth $34,315,000 after acquiring an additional 334,617 shares during the period. Capital International Investors lifted its stake in shares of Agios Pharmaceuticals by 10.4% in the 3rd quarter. Capital International Investors now owns 3,096,422 shares of the biopharmaceutical company’s stock worth $238,796,000 after acquiring an additional 291,393 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Agios Pharmaceuticals by 2.7% in the 3rd quarter. Vanguard Group Inc. now owns 4,251,439 shares of the biopharmaceutical company’s stock worth $327,871,000 after acquiring an additional 109,849 shares during the period. 95.33% of the stock is owned by institutional investors.
In other news, Director John Maraganore sold 13,555 shares of the business’s stock in a transaction that occurred on Tuesday, September 11th. The shares were sold at an average price of $72.75, for a total transaction of $986,126.25. Following the sale, the director now owns 38,609 shares in the company, valued at $2,808,804.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Scott Biller sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, October 5th. The shares were sold at an average price of $69.79, for a total transaction of $209,370.00. Following the sale, the insider now owns 53,932 shares in the company, valued at approximately $3,763,914.28. The disclosure for this sale can be found here. Insiders have sold 19,555 shares of company stock worth $1,404,566 in the last 90 days. 3.02% of the stock is owned by company insiders.
AGIO stock opened at $53.17 on Friday. Agios Pharmaceuticals Inc has a 12 month low of $51.37 and a 12 month high of $99.82.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.01). Agios Pharmaceuticals had a negative net margin of 461.78% and a negative return on equity of 48.51%. The business had revenue of $15.20 million for the quarter, compared to analyst estimates of $22.72 million. During the same period in the prior year, the company earned ($1.59) earnings per share. The firm’s revenue for the quarter was up 33.8% on a year-over-year basis. On average, equities research analysts forecast that Agios Pharmaceuticals Inc will post -6.12 earnings per share for the current fiscal year.
AGIO has been the subject of several recent research reports. Canaccord Genuity reissued a “buy” rating and set a $90.00 target price on shares of Agios Pharmaceuticals in a research note on Wednesday, September 5th. Cann reissued a “hold” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, September 5th. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, September 6th. ValuEngine lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 11th. Finally, Guggenheim initiated coverage on shares of Agios Pharmaceuticals in a research note on Monday, September 17th. They set a “neutral” rating for the company. Six equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $96.27.
COPYRIGHT VIOLATION NOTICE: “Agios Pharmaceuticals Inc (AGIO) Shares Sold by Marshall Wace North America L.P.” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/12/08/agios-pharmaceuticals-inc-agio-shares-sold-by-marshall-wace-north-america-l-p.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Further Reading: How to calculate the annual rate of depreciation
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.